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Background
CCCTC binding factor, also known as CTCF, has been
described as a gene transcription promoting factor. On a
genome–scale this protein is able to mediate long-range
chromatin interactions enabling the regulation of the
expression of domain genes. On a gene-scale CTCF is
associated with an insulation function that counter propa-
gation of methylation and repressive histone marks, spe-
cially in promoters associated to CpG islands of genes
such as BRCA1, ER, Rb, p16, p53, and miR-125b1. For this
reason CTCF dissociation is associated to epigenetic silen-
cing. CTCF has a paralog gene, CTCFL or BORIS (CTCF-
like or Brother of the Regulator of Imprinted Sites), whose
over-expression has been reported in neoplastic tissue
such as breast cancer. BORIS is endogenously expressed
only in testes, and its gene is epigenetically silenced in all
other cells via DNA methylation. While CTCF is distribu-
ted throughout the nucleus, BORIS is localized in both
nucleolus and nucleus.
Materials and methods
The main interest of our work was to determine whether
BORIS and CTCF were deregulated in breast cancer. First
we analyzed the expression of both genes in three different
cell lines (MCF7, MDA-MB-231, MCF10A) by RT-PCR.
In order to evaluate the sub-cellular localization of BORIS
and CTCF we performed immunofluorescent detection of
both proteins in the three cell lines. As a way of establish-
ing a correlation between cell lines and cancer/neoplastic
tissue, we performed an immunohistochemical staining of
BORIS and CTCF in tissue samples from breast cancer
patients. Sodium bisulfite assays were carried out in order
to elucidate whether the changes in DNA methylation
were responsible for the over-expression of BORIS.
Results
The results suggest that BORIS is abnormally over-
expressed in cancer cell lines. Data showed that in the
non-neoplastic cell line BORIS was found within
the nucleolus, whereas in MCF7 it was only found in the
nucleoplasm. CTCF localization showed no difference
between cell lines. In the breast cancer samples BORIS
was found in the cytoplasm while CTCF was not found
in the aggressive cancer tissue. These data point out that
there might be a deregulation both at protein localization
and gene expression levels. We evidenced a loss of
methylation in the BORIS promoter from the samples of
breast cancer patients in contrast with the normal tissue
samples. A reactivation of BORIS expression in the sam-
ples that exhibited a loss of DNA methylation.
Conclusions
BORIS and CTCF may be deregulated in a model of
breast cancer.
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